Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585108 | 1.00 | TSHR (0.50) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL23482726 | 0.85 | — | — | |
| SCHEMBL8520637 | 0.85 | TSHR (0.42) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL4291258 | 0.85 | — | — | |
| SCHEMBL8530023 | 0.84 | TSHR (0.38) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL8084261 | 0.84 | TSHR (0.38) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL8084257 | 0.84 | TSHR (0.38) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL25599316 | 0.83 | TSHR (0.41) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL8091033 | 0.82 | CNR2 (0.38) | TSHRGABRR1GABRR2BLMLMNA | |
| SCHEMBL8091035 | 0.82 | CNR2 (0.38) | TSHRGABRR1GABRR2BLMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | claimed |
| JP-11148089-A | — | — | None | — | — | JP | disclosed |
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-2225272-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | Enkam Pharmaceuticals A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| EP-1660539-B1 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009068042-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | disclosed |
| JP-H11148089-A | LIQUID DETERGENT COMPOSITION | LION CORP | 1999-06-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | TSHR 1222/4885GABRR1 877/4885GABRR2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.